Paradigm shift in inflammatory bowel disease management: precision medicine, artificial intelligence, and emerging therapies
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
inflammatory bowel disease Crohn’s disease ulcerative colitis
Fecha
2025-02-25Referencia bibliográfica
Caballero Mateos, A.M.; Cañadas de la Fuente, G.A.; Gros, B. Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies. J. Clin. Med. 2025, 14, 1536. https://doi.org/ 10.3390/jcm14051536
Resumen
Inflammatory bowel disease (IBD) management stands at the cusp of a transformative era, with recent breakthroughs heralding a paradigm shift in treatment strategies.
Traditionally, IBD therapeutics revolved around immunosuppressants, but the landscape
has evolved significantly. Recent approvals of etrasimod, upadacitinib, mirikizumab, and
risankizumab have introduced novel mechanisms of action, offering renewed hope for
IBD patients. These medications represent a departure from the status quo, breaking
years of therapeutic stagnation. Precision medicine, involving Artificial Intelligence, is
a pivotal aspect of this evolution, tailoring treatments based on genetic profiles, disease
characteristics, and individual responses. This approach optimizes treatment efficacy,
and paves the way for personalized care. Yet, the rising cost of IBD therapies, notably
biologics, poses challenges, impacting healthcare budgets and patient access. Ongoing
research strives to assess cost-effectiveness, guiding policy decisions to ensure equitable
access to advanced treatments. Looking ahead, the future of IBD management holds great
promise. Emerging therapies, precision medicine, and ongoing research into novel targets
promise to reshape the IBD treatment landscape. As these advances continue to unfold,
IBD patients can anticipate a brighter future, one marked by more effective, personalized,
and accessible treatments.